Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lahti, A.
Right arrow Articles by Tamminga, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lahti, A.
Right arrow Articles by Tamminga, C.
American Journal of Health-System Pharmacy, Vol 52, Issue suppl_1, S5-S8
Copyright © 1995 by American Society of Health-System Pharmacists

Articles

Recent developments in the neuropharmacology of schizophrenia

AC Lahti and CA Tamminga


Recent developments in the neuropharmacology of schizophrenia are discussed. Research in the pathophysiology of schizophrenia has enhanced our understanding of the illness and contributed to the development of new drug therapies. With magnetic resonance imaging and positron emission tomographic scans, we are able to examine the structure and function of the brain in living schizophrenic patients. Molecular biologic techniques have been used to identify several types of dopamine receptors; these may play a key role in the pathogenesis of schizophrenia. New drug therapies have been developed that target specific receptors in the brain. Antagonists of dopa-mine and serotonin receptors were developed on the basis of the discovery that dopa-minergic and serotonergic systems in the mammalian central nervous system functionally interact; balanced antagonism of these receptors may provide an enhanced antipsychotic effect.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
L. S. Tyler, S. W. Cole, J. R. May, M. Millares, M. A. Valentino, L. C. Vermeulen Jr., A. L. Wilson, and DEVELOPED BY AN ASHP EXPERT PANEL ON FORMULARY MAN
ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System
Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1272 - 1283.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Society of Health-System Pharmacists.